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SERUM PHOSPHORUS LEVELS AND COGNITIVE PERFORMANCE  
 
IN THE FRAMINGHAM OFFSPRING COHORT STUDY  
DANIEL ALEXANDER DANILUK 
ABSTRACT 
Background 
With the proportion of the world’s elderly population continuing to increase dramatically, 
tremendous amounts of research have focused on detecting the earliest signs of cognitive 
impairment before the onset of dementia. The pathophysiology of dementia is complex 
and recent genetic and biomarker studies have identified new biological pathways that 
might modify the risk of dementia. One potential risk factor, altered serum phosphorus 
levels, has been studied with respect to its potential impact on human cognition. The 
association between serum phosphorus and cognition needs further investigation using a 
population that is free of CKD. 
 
Objective 
I used data from the Framingham Offspring Study (FOS) cohort to investigate the cross-
sectional association between measured serum phosphorus within the normal range and 
cognitive performance in women and men. 
 
Methods 
Participants from the FOS who attended the ninth examination cycle were included in 
this analysis (N=1253). The Wechsler Memory Scale: Logical Memory – Immediate and 
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Delayed recall (LM-IR and LM-DR) and Visual reproduction – Immediate and Delayed 
recall (VR-IR and VR-DR) tests were used to assess verbal and visual memory, 
respectively. Times for the Trailmaking Test – Parts A and B along with the difference 
between the two tests (B-A) were used to assess attention, psychomotor speed, and 
executive functioning. Participants were categorized according to levels of fasting serum 
phosphorus as follows: Low Phosphorus - 2.0-<3.1 mg/dL for men and 2.6-<3.6 mg/dL 
for women, Moderate Phosphorus - 3.1-<3.6 mg/dL for men and 3.6-<3.9 mg/dL for 
women, High Phosphorus - 3.6-<5.2 mg/dL for men and 3.9-<5.3 mg/dL for women. 
Mean cognitive scores were compared across categories using a least squares general fit 
linear model. Multivariable logistic regression models were used to investigate the 
association between higher serum phosphorus levels and odds of cognitive impairment 
within each cognitive test. 
 
Results 
We did not find any statistically significant differences in mean scores on the Logical 
Memory, Visual Reproduction,  and Trailmaking – Part A tests among the categories of 
fasting serum phosphorus. There was no association between higher serum phosphorus 
levels and odds of cognitive impairment on any of the verbal and visual memory tests. In 
men, higher serum phosphorus levels were associated with poorer performance on the 
Trailmaking Test – Part B (High phosphorus: -0.50 ± 0.04, Moderate phosphorus: -0.40 ± 
0.03, Low phosphorus 
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: -0.33 ± 0.04; P-trend: <0.002) and the difference in log-transformed times between the 
Trailmaking Test – Part B and A tests (High phosphorus: -1.16 ± 0.02, Moderate 
phosphorus: -1.10 ± 0.02, Low phosphorus: -1.07 ± 0.02; P-trend: <0.004). Higher serum 
phosphorus levels were associated with an 80% greater odds of having a cognitively 
impaired score on Trailmaking Test – Part B-A in men (OR: 1.81, 1.11-2.94), and this 
association was strengthened when adjusting for additional confounding variables (OR: 
2.02, 1.15-3.54). There was no such association in women. Using a cubic spline 
regression analysis, we treated serum phosphorus as a continuous variable and observed a 
positive linear association between phosphorus and total time or Trailmaking – Part B-A 
in men. In particular, the odds of cognitive impairment increased at levels of phosphorus 
above 3.5 mg/dL. 
 
Conclusions 
This study demonstrated that higher serum phosphorus levels were associated with poorer 
performance on the Trailmaking Test – Part B, and in times represented by the 
Trailmaking Test – Part B-A time in men. We also observed that higher fasting serum 
phosphorus levels as a continuous variable were associated with increased odds of 
cognitive impairment on Trailmaking Test – Part B-A in men. We found no association 
between higher serum phosphorus levels and lower verbal and visual memory scores or 
increased odds of cognitive impairment on those scores. Since fewer women had 
cognitive impairment on these test, statistical power was limited for some of these 
analyses. Future studies are necessary to examine the mechanistic pathways by which 
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serum phosphorus could impact cognition and whether these effects are independent of 
cardiovascular disease. 
Keywords: cognitive performance, verbal memory, visual memory, executive 
functioning, serum phosphorus, epidemiology  
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	 	With the proportion of the world’s elderly population continuing to increase 
dramatically 1, research has increasingly focused on detecting the earliest signs of 
cognitive impairment before the onset of dementia 2. Decline in overall cognitive 
function is typical of normal aging, but clinicians face the challenge of distinguishing 
normal aging from clinically significant impairment 3. 
The increase in the world’s aging population has also lead to an increase in 
prevalence of dementia. There are an estimated 46 million people living with dementia 
worldwide 4, with estimates expected to rise to 135 million by 2050 5. As a result of this 
increased burden of dementia, total global economic costs which were estimated to be 
$818 billion in 2015 6 and are currently estimated to cost $1 trillion 4. Cognitive 
impairment and dementia are neurocognitive disorders without a cure or encouraging 
prognosis. Therefore, a method for easily identifying risk factors for dementia is 
necessary for preventing cognitive decline and is a public health priority. One such 
potential risk factor, altered serum phosphorus levels, is easily measured and has the 
potential to impact human cognition. 
 
Main Functions of Phosphorus in the Human Body 
Inorganic phosphorus in the form of phosphate (PO43-) is essential for human life 
and a key component of organic phosphates, nucleic acids, and adenosine triphosphate 
(ATP) 7. Phosphorus is an important macronutrient for central nervous system 
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functioning and is found abundantly in the brain 8. About 4.29% of the adult human body 
is composed of phosphorus 9. Roughly 80–90% of the human body’s phosphorus is found 
in the teeth and bones in the mineral form of a calcium phosphorus salt known as 
hydroxyapatite 7. 
Phosphorus concentrations in serum are determined by intestinal absorption of 
phosphate from the diet, release from the bones and soft tissues, and excretion through 
the feces and urine 10. The normal range for serum phosphorus concentrations is between 
2.5-4.5 milligrams/deciliter (mg/dl) (0.80–1.45 millimole/liter [mmol/l]) under 
physiological conditions 11. Phospholipids contain phosphorus and are a part of the cell 
membrane’s major structural component 12. Phosphate groups make one of the three parts 
of a nucleotide, which are used in a variety of roles in cellular metabolism such as energy 
currency, structural components in enzyme cofactors and metabolic intermediates, and 
the constituents of nucleic acids 12. Phosphorylation of many biological metabolites and 
compounds is necessary for normal human functioning. ATP, described as the basic unit 
of energy in cells, is a major chemical compound in energy balance, transfer, and storage, 
being the main provider of free phosphates to activate enzymes 12. 
Phosphorus is abundant in the diet of modernized countries, with average intakes 
being much higher than the recommended amount of 700 milligrams (mg) per day 13. The 
United States Department of Agriculture’s National Health and Nutrition Examination 
Survey (NHANES) found that from 2001-2014 the highest sources of dietary phosphorus 
were grains, meat, seafood, and milk in adults 14. Soft drinks have also been shown to 
contribute significantly to increased dietary phosphorus intake 15. More often than not, if 
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an individual is ingesting enough protein, then they have a sufficient phosphorus intake13. 
Higher serum phosphorus levels have been found to increase the risk of 
cardiovascular disease (CVD) and all-cause mortality 16. The National Kidney 
Foundation Kidney Disease Outcome Quality Initiative has recommended monitoring 
serum phosphorus levels, restricting dietary phosphorus intake, and using intestinal 
phosphorus blockers as a treatment for patients with Chronic Kidney Disease (CKD) 
stages 3-5 and hyperphosphatemia in an effort to normalize levels to within the normal 
range and reduce risk of CVD and other adverse health outcomes 17. The Kidney Disease 
Improving Global Outcomes based these suggestions on the surge of evidence showing 
an association between higher serum phosphorus concentrations and increased risk of 
worse health outcomes in CKD patients 18. 
 
Phosphorus Metabolism  
Serum phosphorus levels are subject to homeostatic regulation in the skeleton, 
intestine, and kidneys 19. This regulatory system is frequently called the gastrointestinal-
bone-renal-parathyroid axis. Fibroblast growth factor 23 (FGF23), parathyroid hormone 
(PTH), vitamin D status, and other regulatory factors and hormones all tightly regulate 
phosphorus processes 13. Defects in the aforementioned hormones relating to bone 
metabolism could be attributed to the association exhibited between serum phosphorus 





FGF23 is a phosphatonin secreted by osteocytes and osteoblasts 20 that is 
responsible for phosphate and vitamin D metabolism, and the last member of the FGF 
family 21. It is thought to be the main essential regulatory hormone in phosphorus 
metabolism and its main function on phosphate homeostasis only became apparent within 
the last 20 years 22. FGF23 increases urinary excretion and decreases reabsorption of 
phosphate by suppressing phosphate reabsorption in proximal tubules 21, 23. FGF23 also 
acts by intestinal phosphate absorption through lowering 1,25-dihydroxyvitamin D 
[1,25(OH)2D] levels. Higher circulating FGF23 levels have been associated with 
increased incidence of dementia 24, suggesting that FGF23 levels may contribute to any 
possible associations observed between serum phosphorus and cognition. In mice, an 
injection of FGF23 reduced serum 1,25(OH)2D levels by inhibiting the expression of the 
enzyme 25-hydroxyvitamin D [25(OH)D]-1α-hydroxylase and enhancing 25(OH)D-24-
hydroxylase expression 25. Thus, highly elevated FGF23 levels are related to abnormally 
decreased phosphorus levels that can lead to hyperphosphaturia and alter 1,25(OH)2D 
levels, and thus need to be taken into consideration in statistical analysis. 
 
PTH 
PTH is a polypeptide hormone that is secreted by the parathyroid gland in 
response to changes in calcium and phosphate levels 26. It is found to regulate serum 
phosphate levels by acting on several organs in the body, including the bones, the 
kidneys, and the small intestine. In the bones, PTH stimulates expression of receptor 
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activator of nuclear factor kappa-Β ligand inducing monocytes to become osteoclasts 
causing the release of calcium and phosphate into the blood 26. In the kidneys, PTH 
decreases phosphate reabsorption, increases calcium reabsorption, and stimulates the 
production of 1α-hydroxylase to increase serum 1,25(OH)2D levels 27. The overall effect 
is increased loss of phosphate in urine. Elevated serum phosphorus concentrations 
stimulate PTH secretion and 1,25(OH)3\2D inhibits PTH production 26, 28. In 
hypocalcemic conditions, the role of PTH in increasing serum calcium concentrations 
leads to reductions in the concentration of serum phosphate. Patients with 




Vitamin D is a group of fat-soluble secosteroids with the major function of 
maintaining serum calcium concentrations within the normal physiological range 29. 
Vitamin D produced in the skin by exposure to the sun is metabolized in the liver and 
kidneys 30. 1,25(OH)3D is strongly stimulated by PTH, while also suppressing PTH 
activity 19. This leads to 1,25(OH)2D regulating serum phosphorus concentration by 
directly increasing intestinal absorption and indirectly increasing renal reabsorption 
through reducing PTH activity. With low serum 25(OH)D concentrations causing a 
deficiency, secondary hyperparathyroidism occurs and causes a renal loss of phosphate 
and decreased intestinal absorption of phosphorus affecting the serum concentration 31. 
The skin’s capacity to produce vitamin D3 is markedly reduced with age 30. The vitamin 
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D receptor is found in most cells and tissues in the body, indicating that a deficiency can 
cause a multitude of problems in the body. 25(OH)D levels are inversely associated with 
increased risk of CVD related outcomes 30. 25(OH)D deficiency increases the risk of 
hypertension, acute myocardial infarctions, atherosclerosis, arterial calcification, and 
peripheral vascular disease 32. Insufficient 25(OH)D levels have been studied as a 
possible risk factor for neurocognitive diseases and decline. Vitamin D status been 
associated with poorer neuropsychological function and lower hippocampal volumes 33. 
Vitamin D deficiency has also been linked with an increased risk of all-cause dementia 
and AD 27, 34. It’s becoming clearer that deviations in hormones related to bone 
metabolism affect other regions of the body, with serum phosphorus having a possible 
role as a risk factor for cognitive decline. 
 
Serum Phosphorus and Cognition 
Abnormal serum phosphorus levels have been implicated as a risk factor for 
cognitive impairment in both adults with chronic kidney disease and healthy populations 
13, 35. Impaired renal function increases with age in association with changes such as 
reduced glomerular filtration rate (GFR), creatinine clearance, and renal blood flow 36. 
These age-related changes can be concurrent with increased risk of cognitive impairment 
and dementia. CKD has been associated with cognitive impairment and dementia; this 




 In a landmark study, Li et al. found that participants with serum phosphorus 
levels in Quintiles 4 (>3.5-≤3.9 mg/dL) and 5 (>3.9 mg/dL) had a statistically 
significantly increased risk of developing incident dementia when compared with 
participants in Quintile 1 (>2.9-≤ 3.2 mf/dL) (Quintile 4: Hazard Ratio [HR =1.05; 95% 
Confidence Intervals [95% CIs]: [1.01–1.10] and Quintile 5: (HR = 1.14; CI: [1.09–
1.20]) (Normal range of assay not reported) (Li). A limitation of this study was that 
serum phosphorus levels were not always measured during the fasting state 39. 
Slinin et al. found that higher fasting serum phosphorus levels were associated 
with increased odds of having cognitive impairment at baseline on an executive function 
test when compared with participants in the lowest group of serum phosphorus (Quartile 
Ranges: Q1, 1.8–2.8 mg/dL; Q2, 2.9–3.1 mg/dL; Q3, 3.2–3.4 mg/dL; Q4, 3.5–6.8 mg/dL. 
Compared with those in Q1, the odds ratio in Q2 was=1.12 (95% CIs: 0.83–1.52); in Q3: 
1.31 (CIs: 0.97–1.77), and Q4: 1.45 (1.08–1.94) (Normal range of assay reported as: 2.5–
4.9 mg/dL) 40. 
On the contrary, limited evidence suggests that lower serum phosphorus could 
also have deleterious effects on the nervous system. Subhash et al. found that although 
non-fasting serum and cerebrospinal fluid phosphorus levels were higher in older (mean 
age=50.7 yrs) adult controls (serum phosphorus=5.56 ± 2.35 mg/dL, normal range not 
reported) than younger (mean age=24.8) adults (serum phosphorus=3.37 ± 0.47 mg/dL), 
levels were significantly lower in patients with AD and dementia (mean age: 61.0 yrs: 
serum phosphorus 4.36 ± 1.38) than in the control group of older adults 41. Park et al. 
examined relations of serum phosphorus levels with cerebral β-amyloid (Aβ) deposition 
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in subjects with mild cognitive impairment (MCI) and AD, finding that lower serum 
phosphorus levels were correlated with Aβ deposition 42. Li et al. also noted in their study 
that participants in the first quintile of serum phosphorus had an increased risk of incident 
dementia (Q1: ≤ 2.9 mg/d; HR=1.09; CI: [1.05-1.14]) when compared with the referent 
group (Q2: >2.9-≤ 3.2 mg/dL) 39. 
Based on limited literature, perturbations in serum phosphorus levels seem to 
have a role in cognitive health. More research is needed to understand this possible role 
and whether serum phosphorus is independently driving these associations or whether 
other related diseases such as CVD might be responsible. 
 
Serum Phosphorus and CVD 
Higher serum phosphorus levels have been associated with higher risk of 
developing CVD and its related outcomes 43-45. This association has been investigated 
thoroughly in those with prevalent CKD. Patients undergoing hemodialysis incur a 
greater risk of developing CVD outcomes likely due to ventricular hypertrophy, 
hypertension, increased inflammation and oxidative stress, chronic volume overload, and 
other associated findings 46. In participants with end-stage renal disease, 
hyperphosphatemia was significantly associated with an increased risk of cardiovascular 
hospitalization 47. Among CKD patients, hyperphosphatemia was found to stimulate 
vascular calcification through increased osteoblast transcription in the vasculature, 
shedding light on the role of higher serum phosphorus levels in atherosclerosis 48. A 
greater prevalence of vascular and valvular calcification was also found in individuals 
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with moderate CKD in the Multi-Ethnic Study of Atherosclerosis (MESA) 49. The same 
study investigators found that higher serum phosphorus concentrations were associated 
with greater arterial stiffness through the ankle brachial index, but not with higher pulse 
pressure 50. 
Higher phosphate levels were found to be correlated with increased 
cardiovascular risk in individuals with and without CKD 43. In the Coronary Artery Risk 
Development in Young Adults study, young adults who were in the highest quartile of 
serum phosphorus level at baseline (Q4: >3.9 mg/dL) were found to have increased odds 
(OR: 2.25, CI: (0.97-5.21) of having a higher coronary artery calcium score 15 years 
later, based on computer tomography, when compared to those in the first quartile (Q1: 
≤3.3 mg/dL) 51. These significantly increased odds were observed in the fully adjusted 
multivariable model that included common CVD risk factors such as age, sex, race, and 
systolic blood pressure 51. In FHS Offspring Study (FOS) participants with normal kidney 
function, higher serum phosphorus concentrations were associated with an increased risk 
of incident CVD [HR: 2.01 (1.27-3.17) for Q4: (3.5-6.2 mg/dL) vs. Q1: (1.6-2.8 mg/dL)] 
45. In this same study, higher serum calcium levels were not associated with a statistically 
significant increased risk of incident CVD [HR: 1.20, CI (0.76-2.67) Q4: (9.9-11.2 
mg/dL) vs Q1: (6.1-9.3 mg/dL)]. Also in FOS participants, Dhingra et al. found that 
participants in the highest quartile of serum phosphorus (Q4: 3.4-4.4 mg/dL for men and 
3.6-4.4 mg/dL for women) had a significantly increased risk of incident heart failure 
[HR: 2.09, CI: (1.28-3.40)] when compared to the first quartile 52. In the Atherosclerosis 
Risk in Communities Study, higher serum phosphorus levels were associated with 
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increased carotid intima-media thickness in men (Q5: >3.8 mg/dL vs. Q1: <3.0 mg/dL, P-
trend=0.008), but not in women (P-trend=0.97) 53. Increased levels of serum phosphorus 
have been associated with vascular calcification and cerebral small vessel ischemic 
disease 48, 54. Narang et al. found a positive association between a moderate increase in 
serum phosphorus levels and increased odds of angiographic severity of coronary artery 
disease (OR: 1.25, CI: (1.06-1.47) with every 0.31 mg/dL rise in serum phosphorus) 55. 
These associations could explain the link between serum phosphorus and CVD, 
through changes in the vasculature of the body. Cerebral small vessel disease and 
cognitive impairment have been associated, while pathological mechanisms for these 
vascular changes leading to dementia have been elucidated 56-58. Serum phosphorus could 
independently induce these vascular changes manifesting in the brain and be linked with 
cognitive impairment or other detrimental changes in cognition. 
 
Sex Differences in Serum Phosphorus Levels 
 Sex differences in serum phosphorus levels and their associations with specific 
health outcomes have been reported by many studies. In the FOS, Dhingra et al. 
performed two studies using data measured during the cohort’s second examination cycle 
45, 52, finding that fasting serum phosphorus levels were significantly lower in men than 
women (numerical amount not reported) after multi-variable adjustments 45; and mean 
levels were on average roughly 0.30 mg/dL lower in men compared with women (3.1 
mg/dL vs. 3.4 mg/dL) 52. Of note, serum calcium levels did not differ between men and 
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women (9.64 ± 0.39 mg/dL in men and 9.58 ± 0.38 mg/dL in women). Onufrak et al. 
examined gender heterogeneity in the association of serum phosphorus levels with 
incident coronary artery disease and all-cause mortality finding that mean baseline levels 
were 0.31 mg/dL lower in men (3.25 mg/dL ± 0.45 mg/dL in men and 3.56 ± 0.46 mg/dL 
in women), although serum calcium levels were not reported in this study 59. As 
previously mentioned, Onufrak et al. found that higher serum phosphorus levels were 
associated with increased carotid intima-media thickness in men, but not in women. In 
patients with CKD, Martín et al. found that in men risk of subclinical atheromatosis was 
elevated with serum phosphorus levels above 3.5 mg/dL (OR: 1.62, CI: 1.09-2.43, p-
value=0.02); while in women, risks increased only with serum phosphorus levels above 
5.0 (OR: 2.94, CI: 1.16-7.43, p-value=0.02) (Martin). Martin et al. also observed that 
serum phosphorus levels decreased in a linear fashion in men as they became older, but 
did not report serum calcium levels 60. In a population free of CKD or CVD, lower serum 
phosphorus was associated with less carotid intima-media thickening in men, but not in 
women 53. 
These sex differences could possibly be explained by changes in estrogen levels 
especially during menopause. In the MESA, postmenopausal women using estrogen 
therapy (ET) had lower mean serum phosphorus (−0.19 mg/dL, (95% CI −0.23, −0.15), 
p-value=<0 .001) and calcium levels (−0.13 mg/dL, 95% CI: −0.17, -0.10, p-value= < 
0.001) than women not on ET, findings that the authors suggest may be associated with 
increased urinary phosphorus excretion 61. In the Heart and Soul Study, when comparing 
women on ET to those who were not, those on ET (mean=3.73 mg/dL, 95% CI: 3.56–
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3.89) had significantly lower serum phosphorus levels than women not on ET 
(mean=4.06 mg/dL, 95% CI: 3.96–4.16) 62. Ix et al. also found that women on ET had 
increased renal phosphate excretion. Concentrations of serum phosphate were 
significantly correlated to circulating estradiol levels with women on ET showing lower 
serum phosphorus levels and increased excretion, the authors suggested that estrogen 
could suppress sodium-dependent phosphorus reabsorption in the renal proximal tubules 
of the kidneys 63. It is clear that these sex-related differences in serum phosphorus levels 
need to be taken into account in future studies. 
 
Study Objective 
The association between serum phosphorus and cognition warrants further 
investigation in a population of healthy older adults without CKD. By using the 
Framingham Offspring cohort, I will investigate this association in such a population. 
The objective of this study is to examine the cross-sectional association between 
measured serum phosphorus and cognitive performance in adults enrolled in the FOS. 
The hypothesis of interest is that measured serum phosphorus levels will be associated 
with cognitive performance in adults. In particular, higher serum phosphorus levels will 
be associated with poorer cognitive performance on neuropsychological tests. With the 
limited literature on this topic focusing on mainly male populations, the findings from 
this study will aid in understanding the possible effects of serum phosphorus on cognition 






 The FHS is a prospective, longitudinal ongoing population-based cohort study 
that arose from the town of Framingham, Massachusetts, USA. The Original cohort 
began recruiting its first participants in 1948 with the aim to identify risk factors that 
contribute to CVD and atherosclerosis 64. At baseline, the FHS cohort enrolled 5,209 
community-dwelling participants aged 28-62 years, who did not exhibit definite signs or 
history of CVD. In 1971, the Offspring cohort was started and recruited the children of 
the Original cohort and their spouses 65. The Offspring cohort enrolled 5,124 participants 
aged 30-61 years who have been studied over 9 examination cycles, with the latest in 
2014. All Offspring cohort participants went through routine physical examinations and 




A flow chart detailing the inclusion and exclusion of participants is detailed in 
Figure 1. For the present analyses, the study sample was selected from participants who 
attended the FHS Offspring cohort visit 7 (1999-2001) and 9 (2011-2014) (N=2430) who 
were between the ages of 46 and 95 and who underwent a neuropsychological assessment 
between 2011 and 2014. Participants with missing data on serum phosphorus (N=1047), 
cognitive test outcomes (N=109), or factors found to be confounders in the final analyses 























Framingham Offspring Cohort participants 
attending Examination Cycle 9 (N=2430) 
Excluded (N=1156): 
x Missing serum phosphorus 
measurement (N=1047) 
x Missing data on at least one of 
the cognitive tests (N=109) 
Attended Examination Cycle 9 and had a 
neuropsychological assessment and serum phosphorus 
measurement (N=1274) 
Final sample of Framingham Offspring Cohort 
participants used in our analysis (N=1253) 
Excluded (N=21): 
x Missing data on at least one of 
the covariates (N=11) 




prevalent dementia (N=10). The final study sample size used for the analysis was 1253 
participants. All participants provided written informed consent, and the study was 
approved by the institutional review board at Boston University Medical Center. The 
study was conducted in accordance with the Helsinki Declaration of 1975. 
 
Assessment of serum phosphorus 
Participants were asked to fast starting at 8:00pm, the evening before their clinic 
exam, for a minimum fasting time of 10 hours. Blood was drawn from participants in a 
supine position, using standard venipuncture techniques, typically between 7:00am and 
9:00am. Specimens were centrifuged for 22 minutes at 2400g at 4°C. Plasma and serum 
were separated from the cells within 90 minutes of draw. Serum phosphorus levels were 
measured using a Roche/Hitachi cobas c 501 analyzer (y) (Roche Diagnostics, Alameda, 
Calif). Lower limits of detection were 0.10 mmol/L (0.31 mg/dL). Serum phosphorus had 
an intra-assay coefficient of variation (CV) of 5.6% 45 and an expected range of 2.5–4.5 
mg/dL. 
 
Cognitive outcome measures and neuropsychological examination 
Cognitive performance was evaluated using a formal neuropsychological 
examination by a trained technician starting in 1999. A test battery consisting of many 
individual neuropsychological tests was combined to examine many different cognitive 
domains, such as memory (verbal and visual), attention, abstract reasoning, word 
retrieval, executive function, motor skills, visuoperceptual skills, and others 66. The 
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examinations were tape recorded to ensure accurate and complete documentation of the 
participants’ responses 67. The domains studied in this analysis include verbal memory, 
visual memory, and executive function. To assess cognitive performance on verbal and 
visual memory, the Wechsler Memory Scale (WMS) Logical Memory – Immediate and 
Delayed recall (LM-IR and LM-DR) and Visual reproduction – Immediate and Delayed 
recall (VR-IR and VR-DR) subtests were used, respectively. The WMS is a battery of 
neuropsychological tests used to assess memory function in an individual. Cognitive 




The WMS-IV (Fourth Edition) 68 LM subtest was used to measure cognitive 
performance on verbal memory. The LM subtest assesses episodic memory in a 
standardized manner 69. The test entails an examiner reading a short prose passage to the 
participant followed by a prompt to immediately recall as many details as possible 
verbatim (LM-IR portion of test) and then again after a 25-35 minute interval (LM-DR 
portion of test). Each test (IR and DR) is computed by adding the number of total correct 
story elements recalled with each test being individually scored. LM-IR and LM-DR each 
have a test score range of 0-24, with each element of the story equating to 1 point. 
 
Visual Reproductions 
The WMS-IV VR subtest was used to assess a participant’s visual memory by 
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examining the participant’s ability to memorize and reproduce the visual stimuli. Four 
designs are used: Design A, B, C-1, and C-2. Designs A and B are shown separately and 
then Designs C-1 and C-2 are shown together. This equates to 3 pictures being presented 
sequentially to the participant on separate pages in a binder. Once each picture is shown 
to the participant for 10 seconds, it is then removed and the participant is asked to 
reproduce the drawing on a piece of paper. Similar to LM-DR, the VR-DR test prompts 
the participant at a later time during the examination to reproduce the original drawings 
as accurately as possible. VR-IR and VR-DR each have a test score range of 0-14. 
Designs A, C-1, and C-2 are given up to 3 points and Design B has a maximum of 5 
points. Each point is assigned for accurately reproducing specific details from each 
design, thus the total score is derived from the number of correct details recalled from 
each design. 
 
Trail Making Tests 
Trailmaking Tests - Parts A and B require the participant to draw a line 
connecting 25 labelled circles scattered over a page 70. In Part A, the circles are numbered 
from 1-25 with the participant asked to connect the circles in ascending order. In Part B, 
the circles are numbered 1-13 and lettered A-L with the participant tasked with 
connecting the circles in ascending order with the added task of alternating between 
numbers and letters. The participant is instructed to complete each test as quickly as they 
can and without lifting their pen. The tester intervenes only to point out that the 
participant has made an error and instructs them to start again from the previous correctly 
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connected circle. The Trailmaking Test – Part A evaluates simple attention, while 
Trailmaking Test – Part B is a more complex testing of attention and requires greater 
cognitive flexibility 66. The Trailmaking Part A and B tests are timed, with the scores 
equating to the completion times in seconds, ranging from 0 to a maximum of 300 
seconds. For these analyses, I included a third variable reflecting executive function, that 
is the time required to complete Part B of the Trailmaking Test minus the time to 
complete Part A of the Trailmaking Test. Calculating the difference in times between the 
Trailmaking Part B and A tests removes the simple sequencing and psychomotor 




Covariates were chosen due to their confounding effects as a result of their known 
or hypothesized associates with cognitive performance and serum phosphorus 
measurements. Participants underwent a physician-administered medical history 
interview at each examination with age, sex, height, and weight being recorded. History 
of CVD, stroke, and frequency of cigarette smoking were also ascertained during these 
examination cycles. Education was categorized into 4 groups (no high school degree; 
high school degree but no college; some college courses with completing the degree; and 
college degree or higher). Apolipoprotein allele ε4 (ApoE ε4) carrier statuses were 
determined through genotyping performed as described by Hixson and Vernier 71. ApoE 
ε4 carrier status has been linked with increased risk of MCI and dementia 72. Body Mass 
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Index (BMI) was calculated by using the following formula: [weight (in kg.)/height (in 
meters)2]. Smoking was converted to “Pack-Years” at exam 9, which was calculated by 
dividing the number of cigarettes smoked per day by 20 and multiplying it by the number 
of years the participant reported smoking 73. Hours of moderate and vigorous physical 
activity were recorded and then weighted as follows: (Number of hours per day of 
moderate*2.4) + (Number of hours of vigorous physical activity)*5. Increased moderate 
and vigorous physical activity has been associated with reduced odds of developing 
cognitive decline 74. Fasting early morning serum samples were used for measurements 
of serum glucose, FGF23, vitamin D status, calcium, and albumin levels. Diabetes 
mellitus was diagnosed on the basis of a history of documented use of either insulin or 
oral hypoglycemic drugs, or a non-fasting plasma glucose level greater than or equal to 
200 mg/dL (11.1 mmol/L) 75. Plasma glucose levels were measured using an intra-assay 
CV of 0.7% and an inter-assay CV of 1.8%. Kidney function was estimated using the 
standardized Chronic Kidney Disease – Epidemiology (CKD-Epi) equation to calculate 
eGFR (estimated GFR) using the following formula: eGFR = 141 x min(SCr/κ, 1)α x 
max(SCr /κ, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if Black] and expressed in 
units of mL/min/1.73m2 76. Serum albumin concentrations were measured using a thin-
film adaptation colorimetric assay of a bromcresol at a pH value of 4.1 with an intra-
assay CV of 0.9, an inter-assay CV of 2.2%, and the normal reference range of 3.5-5.2 
g/dL. Serum calcium concentrations were measured using o-cresolphthalein complexone 
under alkaline conditions 77 with an intra-assay CV of 0.7% and an inter-assay CV of 
1.8% with a expected range of	8.6-10.2 mg/dL. Serum 25(OH)D concentrations were 
	
20	
measured using a radioimmunoassay with total intra- and inter-assay CV for control 
values of 8.5% and 13.2%, respectively, and a mean intra-assay CV of 3.2% 78. The 
expected range of 25(OH)D was 5.0-100.0 ng/ml. Serum PTH concentrations were 
measured using an electroluminescent immunoassay with an intra-assay CV of 2.0% and 
an inter-assay CV of 3.3%, with a normal reference range of 10-300 pg/mL. Serum 
FGF23 concentrations were measured using a multiplex immunoassay with an inter-assay 
CV ranged from 5.49% to 5.68% 24, with an normal reference range of 18-435 RU/mL. 
Serum FGF23 measurements from the seventh examination cycle (1998-2001) were used 




Exploratory analyses were carried out first. Differences in the baseline 
characteristics among quintiles of measured serum phosphorus levels were computed by 
performing analysis of covariance tests for continuous parametric and non-parametric 
variables. A Pearson correlation test was conducted relating 25(OH)D with serum 
phosphorus, calcium, PTH, and FGF23, and  serum PTH with 25(OH)D, calcium, and 
FGF23. Serum phosphorus was subsequently classified into three categories based on 
sex-specific sensitivity analyses as well as consideration of statistical power and 
previously-published cutoff values for higher and lower levels of phosphorus. The three 
categories of serum phosphorus were defined as follows: Category 1: Low Phosphorus - 
2.0-<3.1 mg/dL for men and 2.6-<3.6 mg/dL for women, Category 2: Moderate 
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Phosphorus - 3.1-<3.6 mg/dL for men and 3.6-<3.9 mg/dL for women, Category 3: High 
Phosphorus - 3.6-<5.2 mg/dL for men and 3.9-<5.3 mg/dL for women. During the 
analyses, we excluded participants with a serum phosphorus measure below and above 
the normal range (<2.5 mg/dL and >4.5 mg/dL) to examine any significant differences in 
the results (N=30). There were no significant differences greater than 5% in any of the 
cognitive test scores when excluding these 30 participants and thus we included them in 
the final analysis. 
A least squares general fit linear model was used to determine differences in 
cognitive test scores among sex-specific categories of serum phosphorus as the primary 
exposure variable. Analysis of covariance was used to adjust the mean cognitive scores 
for potential confounding. Multivariate logistic regression models were used to 
investigate the association between higher serum phosphorus levels and odds of cognitive 
impairment using each individual cognitive test. For some analyses, measured serum 
phosphorus was divided into two sex specific groups reflecting lower and higher levels. 
Scores for both logical memory (LM-IR and LM-DR) and visual reproduction memory 
(VR-IR VR-DR) were used to classify subjects as cognitively impaired or not (score <1 
vs. >1 standard deviation (SD) below the mean for each test). The scores on the 
Trailmaking tests right skewed and each Trailmaking test component (Part A, Part B, and 
Part B-A) was dichotomized to reflect impairment as ≥80th vs. <80th percentile for the 
time required to complete the tests. In this case, higher scores reflect greater impairment. 
We also used least squares general fit models based on log-transformed times in minutes 
for the Trailmaking tests to normalize the distributions. Finally, we used logistic 
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regressions models restricted cubic spline functions to examine the dose-response 
relations between phosphorus level and scores on the final Trailmaking test. 
Other covariates were also transformed or categorized as needed as a result of non-
normality. For example, due to the skewed distribution of the “Pack-Years” variable, we 
categorized it into “None or 0 Pack-Years of Smoking”, “1-<20 Pack-Years of Smoking”, 
“20-<30 Pack-Years of Smoking”, and “30+ Pack-Years of Smoking”. A dummy 
variable for “Missing” was used for participants who were missing data on smoking. In 
our first multivariable model, we included only those factors that were found to confound 
the estimated effects (based on a 5-10% change or more in the effect estimates). Factors 
retained in the main model included age, sex, education, prevalent CVD and eGFR. A 
second model additionally adjusted for BMI, diabetes mellitus status, pack-years of 
smoking, ApoE ε4 carrier status, serum calcium, serum albumin, serum 25(OH)D, serum 
PTH, and serum FGF23. Categorical variables are presented as numerals and 
percentages. Continuous variables are listed as means and standard deviations. 
We used sensitivity analyses to explore the removal of certain subjects from the analysis. 
First, participants with an eGFR of <45 mL/min/1.73m2 were excluded due to the known 
cognitive deficits of participants with severe CKD and kidney failure (N=56). Second, 
participants with a history of prevalent stroke (N=32) were excluded due to 
comprehensive evidence linking cognitive deficits with an increased risk of dementia in 
individuals with a stroke event 79. Third, we considered the age distribution of our 
participants as many were quite young during the ninth examination cycle. Therefore, we 
excluded those aged younger than 50 years (N=6). Our sensitivity analyses excluding 
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participants under these three criteria yielded similar results to the primary analyses and 
cognitive test scores differed only in the second decimal (less than a 5% difference). 
Therefore, we included all of these participants in the main analysis to increase statistical 
power. 
Analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, 





	 Baseline characteristics 
The baseline characteristics of the 1253 women and men included in the analysis 
are presented in Table 1 by category of measured serum phosphorus (Low phosphorus: 
2.0-<3.1 mg/dL for men and 2.6-<3.6 mg/dL for women; Medium phosphorus: 3.1-<3.6 
mg/dL for men and 3.6-<3.9 mg/dL for women; High phosphorus; 3.6-<5.2 mg/dL for 
men and 3.9-<5.3 mg/dL for women). The mean age of participants was 70.26 years and 
was similar across phosphorus categories. Overall, mean serum phosphorus was 3.5 
mg/dL, 3.3 mg/dL in men, 3.7 mg/dL in women, and 42.1% of participants had a college 
degree. Those with the highest serum phosphorus levels were more likely to have a high 
school degree or less while those in the lowest category of serum phosphorus levels being 
more likely to be non-smokers. Participants in the highest category of serum phosphorus 
levels made up the largest proportion of “20+” pack-years category (High phosphorus: 
33.3%). The mean eGFR of the sample was 74.23 mL/min/1.73m2 and participants in the 
highest category of serum phosphorus had lower eGFR values than those in the lower two 
categories (eGFR for high phosphorus: 72.72 vs.: 75.04 and 74.82, for medium and low 
categories of phosphorus, respectively). There were no statistically significant differences 
in serum calcium levels among the participants in the 3 phosphorus categories. 
Participants in phosphorus categories 2 and 3 were also more likely to have prevalent 
CVD and diabetes, this difference being more prominent with prevalent CVD (High 




Table 1. Descriptive Characteristics of Participants among Categories of Serum Phosphorus Levels at Exam 9 
Subject Characteristics Total (N=1253) Low Phosphorus† (N= 403) Moderate Phosphorus† (N= 452) High Phosphorus† (N= 398) 
Age, years 70.26 ± 8.02 70.68 ± 7.82 69.96 ± 8.19 70.18 ± 8.02 
Women, n (%) 706 (56.3) 249 (61.8) 206 (45.6) 251 (63.1) 
Education, n (%)     
      High school degree or less 357 (29.3) 115 (32.3) 117 (32.8) 125 (35.0) 
      Some years of college 358 (28.6) 114 (31.8) 140 (39.1) 104 (29.1) 
      College degree 528 (42.1) 164 (31.1) 195 (36.9) 169 (32.0) 
ApoE ϵ4, n (%) 291 (23.2) 80 (19.6) 110 (24.3) 101 (25.4) 
BMI (kg/m²) 28.24 ± 5.35 28.23 ± 5.07 27.85 ± 4.95 28.71 ± 5.98 
Pack-Years of Smoking     
      None or 0 469 (37.4) 172 (36.7) 156 (33.3) 141 (30.1) 
      1-<20 409 (32.6) 124 (30.3) 149 (36.4) 136 (33.3) 
      20+ 312 (24.9) 87 (27.9) 122 (39.1) 103 (33.0) 
Physical Activity, MVPA formula 11.86 ± 8.29 11.98 ± 8.37 12.20 ± 8.63 11.36 ± 7.78 
eGFR, mL/min/1.73m2  74.23 ± 16.02 74.82 ± 15.59 75.04 ± 15.54 72.72 ± 16.90 
Serum phosphorus (mg/dL) 3.53 ± 0.48 3.09 ± 0.31 3.49 ± 0.24 4.04 ± 0.30 
Serum (25(OH)D) (ng/mL) 32.41 ± 10.55 32.96 ±  11.25 31.24 ±  9.29 33.19 ±  11.06 
Serum calcium (g/dL) 9.52 ± 0.41 9.50 ± 0.45 9.50 ± 0.37 9.55 ± 0.40 
Serum albumin (g/dL) 4.46 ± 0.26 4.44 ± 0.27 4.47 ± 0.24 4.46 ± 0.27 
Serum FGF23††  (RU/mL) 45.92 ± 20.61 50.00 ±  24.59 45.03 ± 15.32 42.81 ± 20.81 
Serum PTH (pg/mL) 75.50 ± 46.29 75.50 ± 48.27 75.32 ± 48.54 75.69 ± 41.75 
Prevalent comorbidities     
      CVD, n (%) 200 (16.0) 49 (24.5) 68 (34) 83 (41.5) 
      Stroke, n (%) 32 (2.6) 9 (28.1) 14 (43.8) 9 (28.1) 
      Diabetes, n (%) 160 (12.8) 44 (27.5) 60 (37.5) 56 (35.0) 
Abbreviations: N, number; ApoE4 ϵ4, apolipoprotein E allele 4; BMI, body mass index; eGFR, estimated Glomerular Filtration Rate; (25(OH)D), 25-
hydroxyvitamin D; FGF23, Fibroblast Growth Factor 23; RU/mL, relative units per milliliter; PTH, parathyroid hormone; pg/mL, picograms per milliliter; 
CVD, cardiovascular disease. 
† Low Phosphorus - 2.0-<3.1 (men) and 2.6-<3.6 (women), Moderate Phosphorus - 3.1-<3.6 mg/dL for Men and 3.6-<3.9 (women), High Phosphorus - 3.6-<5.2 
(men) and 3.9-<5.3 (women). 
†† FGF23 measured at Examination cycle 7 (1998-2001) due to lack of measurement at Examination cycle 9.
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Serum phosphorus and Logical Memory scores in All Subjects Combined 
Table 3 shows the mean verbal memory scores for LM-IR and LM-DR tests for 
men and women combined with low, moderate, and high levels of serum phosphorus. 
The results for models 1 and 2 were similar. Participants with low phosphorus levels had 
a mean LM-IR score of 11.92 (± 0.16) compared with those having moderate (LM-IR: 
11.59 ± 0.15) and high levels (LM-IR: 11.75 ± 0.16), respectively. The trend was not 
statistically significant (p-trend=0.45). For the analyses of LM-DR, there was also no 
association across categories of serum phosphorus (p-trend=0.39). Adjusting for 
additional covariates made no difference in the results (p-trend=0.29). 
 
Serum phosphorus and Visual Reproductions scores in All Subjects Combined 
Results for the combined means of scores from the VR-IR and VR-DR tests for 
men and women in each category are shown in Table 3. Both the immediate and delayed 
visual reproduction scores (VR-IR and VR-DR) tended to decline with increasing 
phosphorus levels. These differences between the lowest and highest phosphorus 
categories tended to be stronger for the immediate recall portion of the VR test. 
 
Serum phosphorus and Trailmaking Test times in All Subjects Combined 
Results for the combined means of log-transformed times from the Trailmaking 
Tests – Parts A, B, and B-A for men and women in each category are shown in Table 3. 
In contrast with the logical memory and visual reproduction scores, a higher score on the 
Trailmaking test is associated with poorer cognitive performance. We observed a 
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tendency for two components of the Trailmaking scores (Part B and Part B-A) to increase 
with higher phosphorus levels. While these results were not statistically significant, the 
direction of the results was consistent. Combining men and women in our analysis 
attenuated the significant differences in the log-transformed Trailmaking Test – Part B 





Table 2. Correlations between bone metabolism hormones 
Serum 25(OH)D with Serum Phosphorus, PTH, and FGF23* 
Variable Pearson coefficient P-value 
Serum Phosphorus 0.07 0.03 
Serum Calcium 0.18 <.0001 
Serum PTH -0.19 <.0001 
Serum FGF23 -0.003 0.91 
   
Serum PTH with Serum Phosphorus, 23(OH)D, and FGF23 
Variable Pearson coefficient P-value 
Serum Phosphorus 0.13 <.0001 
Serum Calcium -0.14 <.0001 
Serum FGF23 0.14 <.0001 





Serum phosphorus and Logical Memory scores in Men 
The differences in cognitive test scores among the categories of serum 
phosphorus levels in Men are presented in Table 4. There were 154 men in Low 
phosphorus, 246 in Moderate phosphorus, and 147 in High phosphorus. These sample 
sizes were consistent for each cognitive test. Verbal memory was measured using mean 
scores on the LM-IR and LM-DR tests. Scores for the LM-IR tended to decline with 
increasing phosphorus levels, but this trend was not statistically significant (Low: 11.57 ± 
0.30, Moderate: 11.10 ± 0.23, High: 10.92 ± 0.30; P-trend=0.12 for model 2). LM-DR 
test scores showed a similar trend that was not statistically significant (Low: 10.76 ± 
0.33, Moderate: 10.11 ± 0.25, High: 9.93 ± 0.33; p-trend=0.07). 
 
Serum phosphorus and Visual Reproductions and Trailmaking scores in Men 
The differences in VR-IR, VR-DR, and Trailmaking cognitive test scores among 
the categories of serum phosphorus levels in Men are presented in Table 4. There was a 
non-statistically significant tendency for VR-IR scores to decline with increasing 
phosphorus levels among men. There was no such association observed in VR-DR. 
However, there was a strong tendency for time required to complete the Trailmaking tests 
(Part B and Parts B-A) to increase with increasing levels of serum phosphorus (p-trend 




Table 3. Differences in Cognitive Test Scores among Categories of Serum Phosphorus Levels in Men and Women (N=1253) 
 Adjusted Means ± Standard Error 
 Model 1†† Model 2¶ 




(N= 398) P-trend Low Phos* Mod Phos* High Phos* P-trend 
Logical Memory–Immediate, scores† 11.92 ± 0.16 11.59 ± 0.15 11.75 ± 0.16 0.45 12.03 ± 0.19 11.54 ± 0.17  11.77 ± 0.18 0.33 
Logical Memory–Delayed, scores 11.00 ± 0.18 10.58 ± 0.17 10.78 ± 0.18 0.39 11.12 ± 0.21 10.58 ± 0.19 10.81 ± 0.20 0.29 
Visual Reproductions–Immediate, 
scores 7.66 ± 0.13 7.70 ± 0.12 7.36 ± 0.13 0.09 7.66 ± 0.14 7.71 ± 0.13 7.35 ± 0.14 0.10 
Visual Reproductions – Delayed, 
scores 6.89 ± 0.14 7.03 ± 0.13 6.76 ± 0.14 0.52 6.90 ± 0.15 7.02 ± 0.15 6.80 ± 0.15 0.60 
Log-Transformed Trailmaking Test–
Part A, time in seconds† 0.62 ± 0.02 0.61 ± 0.01 0.60 ± 0.02 0.33 0.62 ± 0.02 0.62 ± 0.02 0.60 ± 0.02 0.56 
Log-Transformed Trailmaking Test–
Part B, time in seconds -0.38 ± 0.02 -0.38 ± 0.02 -0.41 ± 0.02 0.26 -0.37 ± 0.02 -0.38 ± 0.02 -0.42 ± 0.02 0.17 
Log-Transformed Trailmaking Test–
Part B-A, time in seconds -1.10 ± 0.01 -1.10 ± 0.01 -1.11 ± 0.01 0.49 -1.09 ± 0.01 -1.10 ± 0.01 -1.12 ± 0.01 0.24 
Abbreviations: N, number; Phos, phosphorus; Mod, moderate. 
*Category 1: Low Phosphorus - 2.0-<3.1 mg/dL for Men and 2.6-<3.6 mg/dL for Women, Category 2: Moderate Phosphorus - 3.1-<3.6 mg/dL for Men 
and 3.6-<3.9 mg/dL for Women, Category 3: High Phosphorus - 3.6-<5.2 mg/dL for Men and 3.9-<5.3 mg/dL for Women. 
†Cognitive test scores presented as mean scores or times and standard errors. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, serum 






Table 4. Differences in Cognitive Test Scores among Categories of Serum Phosphorus Levels in Men (N=547) 
 Adjusted Means ± Standard Error 
 Model 1†† Model 2¶ 




(N=147) P-trend Low Phos* Mod Phos* High Phos* P-trend 
Logical Memory–Immediate, scores† 11.44 ± 0.26 11.14 ± 0.20 10.88 ± 0.27 0.13 11.57 ± 0.30 11.10 ± 0.23 10.92 ± 0.30 0.12 
Logical Memory–Delayed, scores 10.57 ± 0.28 10.03 ± 0.22 9.90 ± 0.29 0.10 10.76 ± 0.33 10.11 ± 0.25 9.93 ± 0.33 0.07 
Visual Reproductions–Immediate, scores 7.73 ± 0.20 7.80 ± 0.16 7.49 ± 0.21 0.42 7.83 ± 0.23 7.91 ± 0.18 7.53 ± 0.23 0.37 
Visual Reproductions–Delayed, scores 6.74 ± 0.22 7.19 ± 0.18 6.98 ± 0.23 0.44 6.82 ± 0.26 7.33 ± 0.20 7.08 ± 0.25 0.48 
Log-Transformed Trailmaking Test–Part 
A, time in minutes† 0.62 ± 0.03 0.56 ± 0.02 0.57 ± 0.03 0.21 0.62 ± 0.03 0.58 ± 0.02 0.59 ± 0.03 0.42 
Log-Transformed Trailmaking Test–Part 
B, time in minutes -0.33 ± 0.03 -0.43 ± 0.03 -0.49 ± 0.04 <0.002 -0.33 ± 0.04 -0.40 ± 0.03 -0.50 ± 0.04 <0.002 
Log-Transformed Trailmaking Test–Part 
B-A, time in minutes -1.07 ± 0.02 -1.11 ± 0.02 -1.15 ± 0.02 <0.001 -1.07 ± 0.02 -1.10 ± 0.02 -1.16 ± 0.02 <0.004 
Abbreviations: N, number; Phos, phosphorus; Mod, moderate. 
*Category 1: Low Phosphorus - 2.0-<3.1 mg/dL, Category 2: Moderate Phosphorus - 3.1-<3.6 mg/dL, Category 3: High Phosphorus - 3.6-<5.2 
mg/dL. 
†Cognitive test scores presented as mean scores or times and standard errors. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, 
serum parathyroid hormone, and serum fibroblast growth factor 23.
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Serum phosphorus and Logical Memory scores in Women 
The differences in LM cognitive test scores among the categories of serum 
phosphorus levels in Women are presented in Table 5. There was no association between 
LM-IR and LM-DR scores and serum phosphorus levels.  
 
Serum phosphorus and Visual Reproductions scores in Women 
The differences in VR cognitive test scores among the categories of serum 
phosphorus levels in Women are presented in Table 5. Mean scores on the VR-IR test 
tended to trend down with increasing serum phosphorus levels. Similarly, VR-DR test 
scores decreased with increasing serum phosphorus levels. 
 
Serum phosphorus and Trailmaking Test times in Women 
In contrast to the men in our analysis, we did not see any statistically significant 
differences among the categories of serum phosphorus levels in any of the Trailmaking 
tests in Table 5. In fact, there was no consistent direction of the effects in women across 





Table 5. Differences in Cognitive Test Scores among Categories of Serum Phosphorus Levels in Women (N=704) 
 Adjusted Means ± Standard Error 
 Model 1†† Model 2¶ 




(N=251) P-trend Low Phos* Mod Phos* High Phos* P-trend 
Logical Memory–Immediate, scores† 12.28 ± 0.21 11.88 ± 0.23 12.40 ± 0.21 0.69 12.35 ± 0.24 11.80 ± 0.26 12.41 ± 0.23 0.82 
Logical Memory–Delayed, scores 11.35 ± 0.23 10.99 ± 0.26 11.42 ± 0.23 0.82 11.37 ± 0.27 10.91 ± 0.30 11.47 ± 0.26 0.76 
Visual Reproductions–Immediate, scores 7.60 ± 0.16 7.62 ± 0.17 7.27 ± 0.16 0.14 7.52 ± 0.18 7.55 ± 0.20 7.20 ± 0.17 0.20 
Visual Reproductions–Delayed, scores 6.96 ± 0.17 6.86 ± 0.19 6.63 ± 0.17 0.18 6.88 ± 0.19 6.77 ± 0.22 6.60 ± 0.19 0.30 
Log-Transformed Trailmaking Test–Part 
A, time in seconds† 0.62 ± 0.02 0.68 ± 0.02 0.61 ± 0.02 0.60 0.63 ± 0.02 0.67 ± 0.02 0.61 ± 0.02 0.70 
Log-Transformed Trailmaking Test–Part 
B, time in seconds -0.39 ± 0.03 -0.34 ± 0.03 -0.37 ± 0.03 0.48 -0.38 ± 0.03 -0.35 ± 0.04 -0.37 ± 0.03 0.71 
Log-Transformed Trailmaking Test–Part 
B-A, time in seconds -1.11 ± 0.02 -1.09 ± 0.02  -1.09 ± 0.02 0.30 -1.08 ± 0.02 -1.09 ± 0.02 -1.09 ± 0.02 0.60 
Abbreviations: N, number; Phos, phosphorus; Mod, moderate. 
*Category 1: Low Phosphorus - 2.6-<3.6 mg/dL, Category 2: Moderate Phosphorus - 3.6-<3.9 mg/dL, Category 3: High Phosphorus - 3.9-<5.3 
mg/dL. 
†Cognitive test scores presented as mean scores or times and standard errors. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, 
serum parathyroid hormone, and serum fibroblast growth factor 23. 
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Serum phosphorus and Odds of Cognitive Impairment in All Subjects Combined 
Results for our logistical models associating lower and higher serum phosphorus 
levels with odds of cognitive impairment in all subjects combined are shown in Table 6. 
In LM-IR, there were 143 participants with cognitively impaired scores compared with 
1110 who had a normal score.	In LM-DR, there were 168 participants with a cognitively 
impaired score vs. 1085 participants with a normal score. Higher (vs. lower) phosphorus 
levels were not associated with a statistically significant increase in odds of having 
cognitive impairment in either LM-IR (OR=1.34; CI 95%: 0.87-2.06) or LM-DR 
(OR=0.88; CI 95%: 0.58-1.33). In VR-IR, there were 196 participants with a cognitively 
impaired score compared with 1057 with a normal score, and in VR-DR there were 180 
participants with an impaired score and 1073 with a normal score. Participants with high 
phosphorus were not associated with increased odds of having a cognitively impaired 
score in VR-IR (OR=1.17; CI 95%: 0.79-1.75) or VR-DR (OR=0.89; CI 95%: 0.58-1.36). 
For the Trailmaking Tests, in Part A there were 240 participants with a cognitively 
impaired mean log-transformed time and 1013 with a cognitively normal mean log-
transformed time, 246 participants with a cognitively impaired mean log-transformed 
time and 1007 with a cognitively normal mean log-transformed time in Part B, and 247 
participants with cognitively impaired mean log-transformed times compared with 1006 
with cognitively normal mean log-transformed times in Trailmaking Test – Part B-A. We 
did not find any statistically significant association between higher phosphorus levels and 




Serum phosphorus and Odds of Cognitive Impairment in Men 
Results for our logistical models associating lower and higher serum phosphorus 
levels with odds of cognitive impairment in men for each cognitive test are shown in 
Table 7. In LM-IR, there were 82 men with a cognitively impaired score compared with 
465 having normal scores. Higher (vs. lower) phosphorus levels were not associated with 
a statistically significant increase in odds of having cognitive impairment (OR=1.26; CI 
95%: 0.73-2.17). Adjusting for additional confounding in model 2 did not change this 
effect (OR=1.27; CI 95%: 0.69-2.33). In the LM-DR analysis, there were 87 men with an 
impaired cognitive score and 460 with a normal score. As with LM-IR, higher 
phosphorus levels were not associated with a statistically significant increase in odds of 
having cognitive impairment compared with lower phosphorus (OR=0.85; CI 95%: 0.49-
1.50). 
 
For the VR test, we first examined VR-IR in which there were 81 men with impaired 
scores vs. 460 with normal scores. Higher phosphorus was not associated with increased 
odds of having a cognitively impaired score (OR=1.32; CI 95%: 0.76-2.30). Additional 
adjustment in the second model did not alter the results. In VR-DR there were 76 men 
with cognitively impaired scores vs. 471 with normal scores. Similarly, there was no 
association between higher phosphorus and risk of having a cognitively impaired score 




For Trailmaking Test – Parts A and B, there were 124 and 112 men identified with 
cognitively impaired scores vs. 435 and 432 with normal scores, respectively. We did not 
find an association between higher phosphorus and increased odds of cognitive 
impairment in either Part A (OR=1.04; CI 95%: 0.64-1.68) and Part B (OR=1.42; CI 
95%: 0.86-2.35). The results did not change after adjusting for covariates in the second 
model for either test. Finally, we examined the results associated with the difference 
between the two Trailmaking tests. There were 115 men with impaired scores vs. 432 
with normal scores in Trailmaking Part B-A. Higher phosphorus was associated with 
81% increased odds of having a cognitively impaired score (OR=1.81; CI 95% 1.11-
2.94). This effect was strengthened after adjustments for additional factors in Model 2 




Table 6. Association between Higher Serum Phosphorus Levels* and Odds of Cognitive Impairment in All Subjects Combined† 
 Total (N=1253) Odds Ratios (95% CIs) 
Cognitive Test Impaired Normal Model 1†† Model 2¶ 
Logical Memory – Immediate 143 1110 1.24 (0.84-1.83) 1.34 (0.87-2.06) 
     
Logical Memory – Delayed 168 1085 0.93 (0.64-1.34) 0.88 (0.58-1.33) 
     
Visual Reproductions – Immediate 196 1057 1.32 (0.93-1.86) 1.17 (0.79-1.75) 
     
Visual Reproductions – Delayed 180 1073 0.97 (0.67-1.41) 0.89 (0.58-1.36) 
     
Trailmaking Test – Part A 240 1013 1.05 (0.76-1.46) 1.12 (0.77-1.62) 
     
Trailmaking Test – Part B 246 1007 1.20 (0.86-1.68) 1.33 (0.91-1.94) 
     
Trailmaking Test – Part B-A 247 1006 1.21 (0.87-1.68) 1.38 (0.96-1.99) 
     
Abbreviations: N, number; CIs, Confidence Intervals. 
*Category 1: Low Phosphorus - 2.0-<3.6 mg/dL for Men and 2.6-<3.9 mg/dL for Women, Category 2: High Phosphorus - 3.6-<5.2 mg/dL for 
Men and 3.9-<5.3 mg/dL for Women. 
†Categories of cognitively normal and impaired scores and times for each cognitive test are described within the statistical analysis segment of 
the methods section. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, 
serum parathyroid hormone, and serum fibroblast growth factor 23. 
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Serum phosphorus and Odds of Cognitive Impairment in Women 
Results for the logistical models evaluating lower and higher serum phosphorus 
levels with odds of cognitive impairment in women are shown in Table 8. There was no 
association between higher serum phosphorus and increased odds of a cognitively 
impaired score (OR=1.23; CI 95%: 0.70–2.18) on the LM-IR test. Further adjustment in 
model 2 led to some strengthening of the OR estimate but none of these results were 
significantly significant (OR=1.40; CI 95%: 0.73–2.69). In the LM-DR analysis, higher 
phosphorus levels were not associated with increased odds of having a cognitively 
impaired score in either model 1 or 2. The results were similar for the immediate and 
delayed VR tests. For the Trailmaking Test – Part A and B, there were 116 and 114 with 
impaired scores and 590 and 572 with normal scores, respectively. In Part A, we found 
no association between higher phosphorus levels and increased odds of cognitive 
impairment (OR=1.14; CI 95%: 0.72–1.78 for model 1; OR=1.11; CI 95%: 0.67–1.81 for 
model 2). Similarly, there was no association between phosphorus level and impaired 
scores on Trailmaking - Part B. In Trailmaking Test – Parts B, higher serum phosphorus 
levels were also not associated with increased odds of having a cognitively impaired 
score (OR: 0.90, 0.57–1.41). The effect was unchanged after adjustment for additional 





Table 7. Association between Higher Serum Phosphorus Levels* and Odds of Cognitive Impairment in Men† 
 Total (N=574) Odds Ratios (95% CIs) 
Cognitive Test Impaired Normal Model 1†† Model 2¶ 
Logical Memory – Immediate 82 465 1.26 (0.73-2.17) 1.27 (0.69-2.33) 
     
Logical Memory – Delayed 87 460 0.85 (0.49-1.50) 0.77 (0.40-1.45) 
     
Visual Reproductions – Immediate 81 466 1.32 (0.76-2.30) 1.30 (0.66-2.55) 
     
Visual Reproductions – Delayed 76 471 0.81 (0.44-1.50) 0.68 (0.33-1.42) 
     
Trailmaking Test – Part A 124 423 1.04 (0.64-1.68) 1.24 (0.71-2.19) 
     
Trailmaking Test – Part B 112 435 1.42 (0.86-2.35) 1.47 (0.81-2.66) 
     
Trailmaking Test – Part B-A 115 432 1.81 (1.11-2.94) 2.02 (1.15-3.54) 
     
Abbreviations: N, number; CIs, Confidence Intervals. 
*Category 1: Low Phosphorus - 2.0-<3.6 mg/dL for Men and 2.6-<3.9 mg/dL for Women, Category 2: High Phosphorus - 3.6-<5.2 mg/dL for 
Men and 3.9-<5.3 mg/dL for Women. 
†Categories of cognitively normal and impaired scores and times for each cognitive test are described within the statistical analysis segment of 
the methods section. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, 





Table 8. Association between Higher Serum Phosphorus Levels* and Odds of Cognitive Impairment in Women† 
 Total (N=706) Odds Ratios (95% CIs) 
Cognitive Test Impaired Normal Model 1†† Model 2¶ 
Logical Memory – Immediate 61 645 1.23 (0.70-2.18) 1.40 (0.73-2.69) 
     
Logical Memory – Delayed 81 625 0.98 (0.59-1.63) 0.94 (0.53-1.67) 
     
Visual Reproductions – Immediate 115 591 1.28 (0.82-2.00) 1.07 (0.64-1.80) 
     
Visual Reproductions – Delayed 104 602 1.09 (0.68-1.76) 0.94 (0.54-1.63) 
     
Trailmaking Test – Part A 116 590 1.14 (0.72-1.78) 1.11 (0.67-1.87) 
     
Trailmaking Test – Part B 134 572 1.11 (0.71-1.74) 1.26 (0.75-2.12) 
     
Trailmaking Test – Part B-A 132 574 0.90 (0.57-1.41) 1.01 (0.60-1.68) 
     
Abbreviations: N, number; CIs, Confidence Intervals. 
*Category 1: Low Phosphorus - 2.0-<3.6 mg/dL for Men and 2.6-<3.9 mg/dL for Women, Category 2: High Phosphorus - 3.6-<5.2 mg/dL for 
Men and 3.9-<5.3 mg/dL for Women. 
†Categories of cognitively normal and impaired scores and times for each cognitive test are described within the statistical analysis segment of 
the methods section. 
††Model 1 adjusted for age, sex, education, prevalent cardiovascular disease, and estimate glomerular filtration rate. 
¶Model 2 additionally adjusted for body mass index, pack years of smoking, prevalent diabetes, serum calcium, serum albumin, serum 25(OH)D, 
serum parathyroid hormone, and serum fibroblast growth factor 23.
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Association of serum phosphorus as a continuous variable and odds of cognitive 
impairment on Trailmaking Test – Part B-A 
 
The results of the logistic regression models using restricted cubic spline 
functions to examine the dose-response relation between serum phosphorus and the odds 
of cognitive impairment on Trailmaking Test, Part B-A are shown in Figure 2. For these 
analyses, we focused on the effects among men since there were no previously identified 
effects of phosphorus on cognitive outcomes in women. These analyses suggest that as 
serum phosphorus increases in men, the level of cognitive impairment on the Trailmaking 




Figure 2. Association of serum phosphorus and odds of cognitive impairment on Trailmaking Test – Part B-A in Men 
 
Abbreviations: 95% CI, 95% Confidence Interval; mg/dL, milligrams per deciliter. 




























	 In this cross-sectional study using the Offspring cohort from the FHS, we found 
that male participants had worse executive functioning scores, as measured by the 
Trailmaking Tests – Part B and the pure measure calculated in Part B-A, when their 
fasting serum phosphorus levels were higher. We observed a trend of increasing mean 
times with each increasing serum phosphorus category. This association was not 
observed in women or the population sample as a whole. We also did not find any 
associations between higher fasting serum phosphorus levels and mean times in the 
Trailmaking Test – Part A. We did not observe any significant differences in scores 
among the categories of serum phosphorus for verbal and visual memory tests. Higher 
phosphorus levels were significantly associated with increased odds of cognitive 
impairment in men, but not in women. We did not observe any significant associations 
between higher fasting serum phosphorus levels and odds of cognitive impairment when 
combining men and women. 
 
Mechanisms 
In our study we saw that higher serum phosphorus levels were associated with a poorer 
performance on executive functioning cognitive tests, but not on verbal or visual memory 
tests. Our observation differs with that seen by Slinin et al. as we did not find an 
association between higher fasting serum phosphorus levels and increased odds of 
cognitive impairment in the Trailmaking Test – Part B 40. Although our findings are 
similar in that we found that higher fasting serum phosphorus levels were associated with 
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increased odds of a cognitively impaired score on executive functioning in men. Of note, 
Slinin et al. measured fasting serum phosphorus level, while not every participant in the 
population sample studied in Li et al. had their serum phosphorus measured during the 
fasting state. It is important that blood samples be taken during the fasting state as dietary 
intake of phosphorus and sugars can significantly increase serum measurements. This 
correlation between higher serum phosphorus levels and cognitive impairment could be 
explained by the aforementioned literature describing the increased risk of CVD in 
healthy individuals. Higher serum phosphorus been cross-sectionally linked to increased 
risk of cardiovascular risk factors in healthy adults. Using data from the NHANES III, 
Kendrick et al. found a strong positive correlation between being in the highest quartile 
of serum phosphorus (3.7–5.0 mg/dL) and odds of having a high ankle brachial pressure 
index (OR: 4.78, CI 1.73–13.2; p-value=0.003) 80. The investigators pointed out that only 
1.5 % of participants had abnormal serum phosphorus levels of >4.5 mg/dL. Park et al. 
observed an association between higher concentrations of serum phosphorus (>3.6 - ≤4.0 
mg/dL) and increased odds of a higher score on a coronary artery calcification index 
(OR: 1.58, CI: 1.04–2.40) in Korean subjects 81. In Korean subjects, Kwak et al. found a 
trend between quartiles of higher serum phosphorus (Q3: 3.6-3.8 mg/dL vs. Q1; OR: 
2.12, CI: 1.64–2.74), serum calcium (Q3: 9.5–9.7 vs. Q1; OR: 1.94, CI: 1.46–2.59), and 
serum calcium-phosphorus product (Q3: 33.3–36.2 vs. Q1; OR: 2.30, CI: 1.74–3.04) and 
a coronary artery calcification score, dietary phosphorus and calcium intake were not 
associated 82. Of note, serum calcium levels did not differ significantly among the 
categories of serum phosphorus and adjustment for calcium in our second model did not 
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significantly alter our results. Shuto et al. observed that high intake of phosphorus led to 
increased reactive oxygen species and inhibition of endothelial nitric oxide species 
leading to endothelial dysfunction in bovine models 83. We adjusted for history of 
prevalent CVD in our analysis, but better measures of coronary calcification such as 
computed tomography imaging would truly show the effect of higher serum phosphorus 
levels on cognition independent of the CVD pathway. Although it is possible that the 
joint effects of higher serum phosphorus levels and the increase in risk of CVD could 
manifest in cognitive impairment before cerebrovascular damage. CVD and vascular risk 
factors have been shown to be correlated with other types of dementia including AD, and 
not just vascular types 84, 85. Ashraf et al. showed increased totals in plasma phosphorus 
(10.50 ± 4.05 mg/dL vs. 4.77 ± 3.19 mg/dL) and calcium concentrations (9.46 ± 3.98 vs.  
7.84 ± 3.47 mg/dL) along with a higher phosphorus/calcium ratio (p-value=2.55 × 10−14) 
in the brains of AD patients when compared to cognitively normal controls 86. Early 
damage to vascular integrity within the brain could drive this association with changes 
such as white matter hyperintensities being predicted to cognitive decline in Trailmaking 
Test – Part B times 87. Although we did not include any magnetic resonance imaging 
(MRI) to relate serum phosphorus levels to changes in the brain using neuroimaging, 
such a study would certainly be warranted. Our findings add to the paucity of research 
and evidence examining the relationship between serum phosphorus levels and cognitive 
function in adults without CKD. It would be of great interest to study the association 
between higher serum phosphorus levels and the longitudinal changes in cognitive scores 
and possibly risk of incident dementia in the FOS, along with incorporating brain MRI 
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measures, in future studies. 
Our associations were only evident in men and not in women or the whole population 
even after adjusting for sex. Li et al. found an association between increased risk of 
developing incident dementia and being in a higher quartile of serum phosphorus in their 
total sample of men and women 39. Although women only accounted for 6.83% of the 
population in Li’s study, as opposed to our sample size which was 53.6% women and the 
investigators did not separate their analysis by sex. Other studies have noted differences 
in cognitive tests and decline between men and women. In the Baltimore Longitudinal 
Study of Aging, McCarrey et al. observed that men experienced a steeper decline in 
cognitive performance on most tests while women did not exhibit a steeper decline over 
men in any test, with one of the exceptions being the Trailmaking Tests – Part A and B 
which showed no differences in decline 88. Maylor et al. found that although men 
performed better on visuo-spatial tests and women better on verbal fluency and memory 
tests, men showed greater age-related cognitive decline than women in all tests 89. 
Conversely, many other studies contend no differences in cognitive decline between 
sexes and this topic has generated controversy. Proust-Lima et al. also found that women 
performed better on verbal fluency tests and men performed better on visuo-spatial tasks, 
but women had a more pronounced cognitive decline than men when examining 
participants in the oldest age group 90. In the Religious Orders Study, Barnes et al. found 
that rates of cognitive decline as measured by a neuropsychological battery of 21 
cognitive tests did not differ among men and women 91. We observed a 0.41 mg/dL mean 
difference in serum phosphorus levels between men (3.30 mg/dL) and women (3.71 
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mg/dL). As mentioned previously in depth, there are many studies reporting higher mean 
serum phosphorus levels in women with factors such as estradiol and use of estrogen-
hormone therapy likely playing a role in these observations. It is possible that the decline 
in executive functioning scores seen in men with higher serum phosphorus levels could 
be attributed to sex-specific hormones such as estradiol and testosterone. Evidence for the 
effects of estradiol and testosterone on serum phosphorus levels in men is limited. In the 
Osteoporotic Fractures in Men Study (MrOS), Meng et al. found that each increased 
10pg/ml increment of total estradiol was associated with a 0.05mg/dL lower serum 
phosphorus levels (CI: −0.09, −0.02; p-value=<0.01) and increased serum testosterone 
levels were associated with lower serum phosphorus levels (β coefficient per 200ng/dL 
greater total testosterone = −0.08; CI −0.13, −0.04; p-value=<0.001) 92. Trends in dietary 
and phosphorus calcium intake across their quartiles of serum phosphorus were not 
significant in this study. Using data from the NHANES III, Wulaningsih et al. found an 
inverse relationship between increasing free testosterone levels and decreasing serum 
phosphorus levels, although this relationship was only significant in non-Hispanic black 
men 93. Higher serum phosphorus levels were previously noted as not being a significant 
risk factor for CVD outcomes in women as opposed to men. By naturally having higher 
serum phosphorus levels, women might be protected from the deleterious effects or have 
physiological advantages and mechanisms that are cardio- and neuroprotective. 
 
Strengths 
My study has much strength including the community-based cohort design and the 
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comprehensive list of covariates that were available in the FHS’s database for the 
Offspring participants. Serum samples were also taken during the fasting state which is a 
more accurate method of measuring serum phosphorus and not performed in studies such 
as those by Li et al 39. While I previously mentioned that Slinin et al. had performed a 
similar study using participants from the MrOS study to assess executive functioning and 
global cognition 40, my present study includes women and adjustments for additional 
covariates such as serum albumin, calcium, 25(OH)D, PTH, and FGF23. To my 
knowledge, no other studies have examined the association between measured serum 
phosphorus levels and cognitive performance on verbal or visual memory tests. These 
covariates have been previously shown to be physiologically related and have very 
significant modifying effects on each other, thus making it imperative to adjust for in an 
analysis. 
In our study, we saw that FGF23 levels decreased with each increasing serum phosphorus 
category (Category 1:	50.00 ± 24.59, Category 2: 45.03 ± 15.32, and Category 3: 42.81 ± 
20.81). This finding is in line with other studies reporting the mechanism of FGF23 
inhibiting renal tubular phosphate excretion 94. In contrast with our findings, Dontae-
Correa et al. found that increased levels of FGF23 were associated with atherosclerosis 
and vascular calcification in patients undergoing open vascular surgery when compared 
to cadaveric organ donor controls without any medical history of CVD 95. Mean serum 
phosphorus and calcium levels were not significantly different between the patients 
(Mean serum phosphorus: 3.6 ± 0.5 mg/dL and mean serum calcium: 9.1 ± 0.5 mg/dL) 
and the controls (Mean serum phosphorus: 3.6 ± 0.6 mg/dL and mean serum calcium: 9.0 
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± 0.6 mg/dL). As such, controlling for serum FGF23 levels presented a great strength for 
our study as it helps distinguish the independent link of higher serum phosphorus levels 
and cognitive performance. 
 
Limitations 
The sample of FOS participants includes mainly Caucasian individuals, and thus restricts 
our ability to generalize the results to any other racial populations. Although the CKD-
EPI equation is a well-validated method of estimating GFR 76, it is not as accurate as the 
measured method. The eGFR will also be less accurate for any participants with unusual 
diets such as vegetarians, other low-meat diets, or any using creatine dietary supplements. 
Due to the observational and cross-sectional nature of this study, we cannot conclude 
causation or exclude any possible residual confounding that was not adjusted for in the 
models. It is possible that the differences in cognitive scores predate the changes in serum 
phosphorus levels. 
 
Dietary Phosphorus Intake and PTH, Vitamin D, and FGF23 
Phosphorus intake is a significant modifier of measured serum phosphorus levels 96,97. 
Thus, it is possible that changes in phosphorus intake could alter serum phosphorus levels 
over time in the FOS cohort, as well as other metabolites used as covariates in this study. 
In a cross-sectional analysis of data from the NHANES, a higher intake of dietary 
phosphates was significantly associated with increased serum phosphorus concentrations 
97. Subjects who were administered a low phosphorus 5-day diet followed by a high 
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phosphorus diet showed concurrent decreases and increases in serum FGF23 levels, 
respectively 98. In another study, participants fed a high phosphate and calcium diet had 
increased serum phosphorus and FGF23 levels, and decreased 1,25(OH)2D and PTH 
levels 99. Food frequency questionnaire data are not available on FOS participants who 
attended the ninth examination cycle. As such, this poses a limitation on our study due to 
the possible changes in serum levels of the aforementioned metabolites over time. 
 
Hormone Replacement Therapy and Cognition 
ET or hormone-replacement therapy (HRT) has been linked to cognition in 
postmenopausal women. The Women’s Health Initiative Memory Study recruited 
participants from the Women’s Health Initiative for a randomized, double-blind, placebo-
controlled trial 100. Shumaker et al. found that women taking estrogen plus progestin had 
a higher risk for dementia than women taking the placebo, but not MCI 100. To determine 
if the same risk applied to women who only took estrogen as their hormone therapy, 
Shumaker reported the results the following year and found that there was no significant 
increased risk of dementia or MCI 101. Resnick et al. performed a standardized set of 
cognitive domain tests on participant and found that verbal memory was negatively 
affected by estrogen plus progestin therapy, but not figural memory 102. Conversely, 
earlier observational studies, such as one conducted by Paganini et al., followed older 
women through a nested case-control study of older women in a retirement community 
and found a reduced risk of Alzheimer’s disease in estrogen users vs. non-users 103. Most 
recently, Matyi et al. followed participants from the Cache County longitudinal study and 
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found that older women who had longer endogenous estrogen exposure and hormone 
therapy were associated with better global cognition later in life 104. The evidence for a 
negative or positive association between ET or HRT and cognitive function has yielded 
mixed findings, further convoluting the topic. Another physiological occurrence to take 
into consideration is that ET has also been associated with serum phosphorus and other 
metabolites involved with bone metabolism. In the MESA study, postmenopausal women 
using ET were found to have lower serum phosphorus and serum calcium levels along 
with higher serum 25(OH)D levels 61. Using data from the NHANES, Zhang et al. found 
that postmenopausal women using estrogen therapy had significantly lower serum 
phosphorus levels than non-users 105. In addition, ET and its possible implications on the 
manifestations of AD and cognitive impairment have been a controversial topic. 
Unfortunately, estrogen-containing hormone replacement therapy use was not recorded at 
the ninth examination cycle in the FOS Cohort. Our lack of ability to adjust our models 
for possible confounding by ET use is a limitation on our study. 
 
Klotho 
Another limitation of this study is our inability to adjust for the enzyme Klotho. Klotho is 
a single-pass transmembrane protein that is predominantly produced in the kidney and is 
linked to aging and other age-related diseases 106. Klotho was first identified by Kuro-o et 
al. through mice that had the homozygous insertional mutation that expressed phenotypes 
similar to human ageing 107. These mice were subsequently named klotho mice. The 
klotho mice had symptoms that included a short life span, growth retardation, 
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arteriosclerosis, ectopic calcification of various organs, osteoporosis, and slight increases 
in serum phosphorus and calcium 107. As such, circulating serum Klotho is a factor that 
has been found to decline with age, indicating that there is a potential link between aging 
and phosphorus metabolism 108. Studies have indicated that higher circulating brain 
Klotho is associated with a lower risk of central nervous system disease, and vice versa 
109. This is likely due to the multitude of brain regions that klotho is expressed including 
the hippocampus, cerebellum, choroid plexus, and the pituitary gland 109. Nagai et al. 
demonstrated that klotho mice have impaired visual recognition memory and associative 
fear memory when reaching the age of week 7, despite having normal functioning at 
week 6 110. In the InCHIANTI study, high serum klotho was related to better global 
cognition and a lower risk of significant decline in Mini-Mental State Exam scores 111. 
Mutated mice with deficient Klotho have increased serum phosphorus, calcium, and 
vitamin D levels, while administration of 1,25(OH)2D3 was found to increase expression 
of Klotho in the kidneys 112. FGF23 requires Klotho as an obligatory co-receptor to form 
a complex to bind with its receptor FGFR23, as FGF23 has a low affinity with its 
receptor without this binding complex 106. Flaws in the gene expression of either 
enzymes, FGF23 or Klotho, result in defective phosphate retention in humans 113. It is 
evident that the previously mentioned bone-intestine-parathyroid-kidney axis is directly 
and indirectly influenced by the interactions of FGF23 and Klotho. Thus, FGF23 and 
Klotho are vital to the metabolism of phosphate and vitamin D. Klotho is especially 
important in this study and its possible confounding effects on phosphate metabolism are 
well known. Serum klotho has not been measured at any exam in the FHS and this lack of 
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data is a limitation for the current study. 
 
CONCLUSIONS 
In conclusion, identifying nutritional biomarkers that could modify cognitive impairment 
through easily accessible laboratory tests is a valuable healthcare and economical goal for 
dementia research. The medical and financial impact of reducing cognitive impairment 
would be astronomical. My present study found that higher serum phosphorus levels 
were associated with poorer performance on the Trailmaking Test – Part B, and in times 
represented by the Trailmaking Test – Part B-A time. We did not find any association 
between higher serum phosphorus levels and lower verbal and visual memory scores or 
increased odds of having a cognitively impaired score. These findings add an interesting 
point to the notion that higher serum phosphorus levels are associated with negative 
health outcomes in individual with healthy kidney function. Future studies are necessary 
to establish if there are mechanistic pathways that serum phosphorus could affect 
cognition independent of CVD and whether these pathways are evident in women. 
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